Physician profile
John Green Malone
NPI 1992773287
$3,849.29
in general payments reported to CMS, 2019-2025
41 companies · $1,442 in 2025
The $1,442 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $0.83 · 2022: $12.16 · 2023: $565 · 2024: $1,830 · 2025: $1,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,836.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $839.88 | 2023-2025 | |
| Pfizer INC. | $243.93 | 2023-2025 | |
| Eisai INC. | $243.57 | 2023-2025 | |
| Neurelis, INC. | $209.18 | 2023-2025 | Valtoco |
| Amgen INC. | $175.01 | 2024-2025 | Uplizna |
| Tg Therapeutics, INC. | $145.90 | 2024 | |
| Lilly USA, LLC | $142.88 | 2024-2025 | Kisunla |
| Ucb, INC. | $139.22 | 2023-2025 | Rystiggo, Briviact, Nayzilam |
| Takeda Pharmaceuticals U.S.A., INC. | $138.37 | 2023-2025 | Hyqvia |
| Mallinckrodt Hospital Products INC. | $128.26 | 2023-2025 | Acthar |
| Vanda Pharmaceuticals INC. | $123.06 | 2025 | Ponvory |
| Emd Serono, INC. | $121.41 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $117.82 | 2025 | |
| Biogen, INC. | $97.38 | 2023-2025 | Skyclarys, Vumerity, Tysabri |
| Teva Pharmaceuticals USA, INC. | $95.90 | 2023-2024 | Austedo Xr |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $95.59 | 2023-2025 | Dysport |
| Scilex Pharmaceuticals INC. | $83.16 | 2023-2024 | Ztlido |
| Averitas Pharma INC. | $69.22 | 2024-2025 | Qutenza |
| Alexion Pharmaceuticals, INC. | $60.51 | 2023-2024 | Ultomiris, Soliris |
| Sk Life Science, INC. | $49.18 | 2024 | |
| Grifols USA, LLC | $47.17 | 2024-2025 | Gamunex-C |
| Jazz Pharmaceuticals INC. | $46.03 | 2023-2025 | Epidiolex |
| Livanova USA, INC. | $44.99 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Lundbeck LLC | $44.88 | 2024-2025 | Rexulti, Vyepti |
| Otsuka America Pharmaceutical, INC. | $42.02 | 2023-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $37.84 | 2023 | Ongentys, Ingrezza |
| Genentech USA, INC. | $35.35 | 2023-2024 | Evrysdi, Ocrevus |
| Catalyst Pharmaceuticals, INC. | $34.59 | 2024-2025 | |
| Sandoz INC. | $27.69 | 2024 | |
| Horizon Therapeutics Plc | $24.93 | 2023 | Uplizna |
| Alnylam Pharmaceuticals INC. | $20.87 | 2024 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $17.48 | 2024 | Wainua |
| Boston Scientific Corporation | $16.08 | 2024 | Watchman Flx |
| Sumitomo Pharma America, INC. | $15.85 | 2023 | Aptiom |
| Axsome Therapeutics, INC. | $15.33 | 2025 | Symbravo |
| Insightec,INC | $13.72 | 2024 | Exablate |
| Celgene Corporation | $13.63 | 2025 | Zeposia |
| Argenx US, INC. | $13.58 | 2024 | Vyvgart Hytrulo |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Linus Health, INC. | $4.84 | 2024 | Core Cognitive Evaluation |
| Travere Therapeutics, INC. | $0.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.